Unexplained lymphadenopathy in homosexual men. A longitudinal study.

Area of Science:

• Immunology
• Virology
• Epidemiology

Background:

• Prospective study initiated by the Centers for Disease Control in January 1982.
• Focused on 78 homosexual or bisexual men presenting with unexplained generalized lymphadenopathy syndrome.
• Investigated the progression and clinical characteristics of lymphadenopathy syndrome.

Purpose of the Study:

• To track the development of acquired immunodeficiency syndrome (AIDS) in individuals with lymphadenopathy syndrome.
• To identify early clinical and laboratory markers predictive of AIDS development.
• To understand the long-term clinical course of lymphadenopathy syndrome.

Main Methods:

• Prospective cohort study design.
• Clinical and laboratory evaluations including T-helper cell counts, hematocrit, lymphocyte counts, and pokeweed mitogen stimulation ratios.
• Serological testing for antibodies to human T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV).

Main Results:

• Antibodies to HTLV-III/LAV were detected in 96% of the study cohort.
• Five percent (6%) of patients were diagnosed with AIDS 5 to 25 months after lymphadenopathy onset.
• Patients who developed AIDS had lower initial T-helper cell counts, hematocrits, lymphocyte counts, and pokeweed mitogen stimulation ratios, and reported more severe symptoms.
• The majority of patients showed little change in initial laboratory and clinical measures during the follow-up period, with unremitting lymphadenopathy features.

Conclusions:

• Generalized lymphadenopathy syndrome, particularly in homosexual/bisexual men, is strongly associated with HTLV-III/LAV infection.
• Early detection of lower T-helper cell counts and specific clinical symptoms may indicate a higher risk of progression to AIDS.
• Lymphadenopathy syndrome represents a significant, often unremitting, clinical condition with a subset progressing to AIDS.